STOCK TITAN

Incannex Healthcare Inc. - $ixhl STOCK NEWS

Welcome to our dedicated page for Incannex Healthcare news (Ticker: $ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incannex Healthcare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incannex Healthcare's position in the market.

Rhea-AI Summary
Incannex Healthcare Ltd (Nasdaq: IXHL) has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD. The Melbourne clinic fit-out is complete, and the clinical and administrative teams are in place. The clinic is the first dedicated Psychedelic-assisted therapy clinic in Australia and has received a substantial number of expressions of interest in treatment submissions from potential patients since opening its application process earlier this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) is developing IHL-42X, a promising drug candidate for obstructive sleep apnea (OSA) treatment. The drug has shown significant efficacy in reducing apnea hypopnea index (AHI) in Phase 2 clinical trials, with potential to address a market of 936 million affected adults worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.45%
Tags
-
Rhea-AI Summary
Incannex Healthcare Inc. (NASDAQ: IXHL) successfully completed its redomiciliation from Australia to the United States, with shares of common stock expected to commence trading on Nasdaq under the symbol 'IXHL' on November 30, 2023. The company will now be subject to the reporting requirements of the SEC and corporate governance rules of Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) announces the approval of the scheme of arrangement for the proposed re-domiciliation from Australia to the United States. The Federal Court of Australia has made orders approving the scheme, with Incannex Healthcare Inc. becoming the ultimate parent company. The company has applied to suspend quotation and trading of shares on ASX, with ADRs continuing to trade on Nasdaq until the implementation date. Shareholders and optionholders will be entitled to receive the Scheme consideration on the implementation date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.28%
Tags
none
-
Rhea-AI Summary
Incannex to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
-
Rhea-AI Summary
Incannex Healthcare prepares IND application for psilocybin therapy, positive interim analysis predicts significant benefit in Phase 2 trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
Rhea-AI Summary
Incannex receives FDA approval for IND opening pivotal IHL-42X Phase 2/3 clinical trial in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
-
Rhea-AI Summary
Incannex subsidiary, Clarion Clinics Group, is now accepting registrations of interest for its psychedelic-assisted therapy treatments. The first clinic in Melbourne is nearing completion and will offer a nine-month treatment program. Treatments will begin after final approval from the Therapeutic Goods Administration. Health authorities estimate that 390,000 Australians suffer from PTSD and 280,000 suffer from treatment-resistant depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
Rhea-AI Summary
Incannex Healthcare Limited has completed a pre-IND meeting with the FDA for its drug product IHL-675A, designed for the treatment of rheumatoid arthritis. The FDA provided valuable feedback and confirmed that no further nonclinical studies are needed for the IND application. They also provided guidance on the requirements for submitting a New Drug Application via the 505(b)(2) pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
none
Incannex Healthcare Inc.

Nasdaq:IXHL

IXHL Rankings

IXHL Stock Data

47.46M
12.79M
21.54%
6.39%
0.56%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
DOCKLANDS, VICTORIA